环状RNA(CircRNAs)已被报道在各种癌症的进展中起关键作用,包括甲状腺癌(TC)。转录因子1(SP1)促进甲状腺癌的发展。这项研究旨在研究Circ0005654与转录因子1(SP1)联合在TC患者中的表达水平,以用于诊断和治疗目的。共有76例甲状腺癌患者接受了根治性手术。术中,收集甲状腺癌组织和配对的癌旁组织及相应的临床病理资料。通过免疫组织化学(IHC)确定甲状腺癌和癌旁组织中SP1和β-catenin的表达,而通过半定量实时聚合酶链反应(sqRT-PCR)测量Circ0005654的表达水平。然后,我们比较了Circ0005654,SP1和Wnt/β-catenin在癌组织和癌旁组织中表达的变异性,并确定了相关分析与甲状腺癌患者临床病理特征之间的关系。借助受试者工作特征(ROC)曲线分析Circ0005654在甲状腺癌组织中的诊断价值,计算术后3年生存率,分析Circ0005654和SP1蛋白水平对患者3年生存率的影响。sqRT-PCR显示Circ0005654在甲状腺癌组织中的表达程度明显高于癌旁组织。Circ0005654的ROC下面积为0.9553,95%置信区间:(0.9211-0.9895),截止值为0.7895,灵敏度为92.11%,特异性为86.84%。免疫组化结果显示,SP1、β-catenin、癌组织中Wnt高于癌旁组织;Circ0005654、SP1、Wnt/β-catenin表达水平与肿瘤直径、淋巴结转移,TNM阶段,和包膜侵入(所有P<0.05)。根据Circ0005654在甲状腺癌组织中的表达水平,高表达组3年生存率为77.5%,低表达组3年生存率为94.4%,差异有统计学意义;SP1阳性和阴性患者3年生存率分别为78.6%和100%,分别,数据明显不同。Circ0005654可作为甲状腺癌诊断的潜在生物标志物,并可能参与甲状腺癌的发展。
Circular RNAs (CircRNAs) have been reported to play key roles in the progression of various cancers, including thyroid cancer (TC). Transcription factor 1 (SP1) promotes the development of thyroid cancer. This study aims at investigating the expression level of Circ0005654 in combination with Transcription factor1 (SP1) in patients with TC for diagnostic and therapeutic purposes. A total of 76 patients with thyroid cancer underwent radical surgery. Intraoperatively, thyroid cancer tissues and paired adjacent tissues and the corresponding clinicopathological data were collected. The expression of SP1 and β-catenin in thyroid cancer and adjacent tissues was determined by immunohistochemistry (IHC) while the Circ0005654 expression level was measured by semiquantitative real-time polymerase chain reaction (sqRT-PCR). Then, we compared the variability of Circ0005654, SP1, and Wnt/β-catenin expression in cancerous and adjacent tissues and determined the relationship between the correlation analysis and the clinicopathological features of the thyroid cancer patients. The diagnostic value of Circ0005654 in thyroid cancer tissues was analyzed with the help of the receiver operating characteristic (ROC) curve, counting the 3-year postoperative survival rate, and analyzing the effect of Circ0005654 and SP1 protein levels on the 3-year survival rate of the patients. sqRT-PCR showed that the expression level of Circ0005654 in thyroid cancer tissue was significantly higher than that of adjacent tissues. The area under the ROC of Circ0005654 was 0.9553, 95% confidence interval: (0.9211-0.9895) with a cutoff value of 0.7895, a sensitivity of 92.11%, and a specificity of 86.84%. The IHC results showed that the expression level of SP1, β-catenin, and Wnt was higher in cancer tissues than in adjacent tissues; Circ0005654, SP1, Wnt/β-catenin expression levels were associated with tumor diameter, lymph node metastasis, TNM stage, and envelope invasion (all P < .05). According to the Circ0005654 expression level in thyroid cancer tissue, the 3-year survival rate of the high expression group was 77.5% and 94.4% in the low expression group with a statistically significant difference; the 3-year survival rate of SP1 positive and negative patients was 78.6% and 100%, respectively, with the data being significantly different. Circ0005654 may serve as a potential biomarker for thyroid cancer diagnosis and may be involved in the development of thyroid cancer.